Search Within

Heather Jolie Landau

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (4)
Groups
  1. Bone Marrow Transplant (10)
  2. Center for Hematologic Malignancies (10)
  3. Department of Medicine (10)
  4. Hematologic Malignancies, Division of (10)
  5. Molecular Imaging and Therapy Service (10)
  6. Radiology, Department of (10)

More Groups

People
  1. Hani Hassoun (8)
  2. Sergio Giralt (7)
  3. Alexander Lesokhin (6)
  4. David Chung (6)
  5. Gunjan Shah (6)
  6. Malin Hultcrantz (5)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2021 (1)
  4. 2020 (3)
  5. 2017 (1)
  6. 2012 (1)

More Years

Publications
  1. Blood (3)
  2. Journal of Clinical Oncology (2)
  3. Bone Marrow Transplantation (1)
  4. Clinical Lymphoma, Myeloma and Leukemia (1)
  5. Journal of Clinical Investigation (1)
  6. Leukemia and Lymphoma (1)

More Publications

Publishers
  1. American Society of Hematology (3)
  2. American Society of Clinical Oncology (2)
  3. Nature Publishing Group (2)
  4. American Society for Clinical Investigation (1)
  5. Elsevier Inc. (1)
  6. Taylor & Francis Group (1)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Accelerated single cell seeding in relapsed multiple myeloma
    Journal Article

    Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
    Nature Communications (2020)

    Fulltext@MSK | Save
  • Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
    Journal Article

    Prockop, S.; Doubrovina, E.; Suser, S.; Heller, G.; Barker, J.; Dahi, P.; Perales, M. A.; Papadopoulos, E.; Sauter, C.; Castro-Malaspina, H.; more...
    Journal of Clinical Investigation (2020)

    Fulltext@MSK | Save
  • Quantitative analysis of T1-weighted MRI images as a surrogate for fat content does not correlate with response or survival
    Meeting Abstract

    Amer, A.; Gunjan, S.; Benjamin, D.; Sean, D.; Molly, M.; Yousef, M.; David, C.; Guenther, K.; Nikoletta, L.; Heather, L.; more...
    Bone Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease
    Journal Article

    Landau, H.; Pandit-Taskar, N.; Hassoun, H.; Cohen, A.; Lesokhin, A.; Lendvai, N.; Drullinsky, P.; Schulman, P.; Jhanwar, S.; Hoover, E.; more...
    Leukemia and Lymphoma (2012)

    Fulltext@MSK | Save
  • FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone
    Meeting Abstract

    Pandit-Taskar, N.; Comenzo, R. L.; Hassoun, H.; Hoover, E.; Borkar, S.; Reidel, E.; Cohen, A.; Surti, C.; Nimer, S. D.; Landau, H. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Sequential administration of bortezomib, liposomal doxorubicin and dexamethasone (BDD) followed by thalidomide and dexamethasone (TD) results in rapid control of untreated high-risk multiple myeloma (MM) and improves depth of response
    Meeting Abstract

    Landau, H.; Hassoun, H.; Cohen, A.; Hoover, E.; Kewalramani, T.; Boruchov, A.; Klimek, V.; Reich, L.; Riedel, E.; Pandit-Taskar, N.; more...
    Blood (2008)

    Fulltext@MSK | Save